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Background: Despite continuous efforts to identify genes that are pivotal regulators of advanced melanoma and
closely related to it, to determine which of these genes have to be blocked in their function to keep this highly
aggressive disease in check, it is far from clear which molecular pathway(s) and specific genes therein, is the
Achilles’ heel of primary and metastatic melanoma. In this report, we present data, which document that the
DEAD-box helicase DDX11, which is required for sister chromatid cohesion, is a crucial gatekeeper for melanoma
cell survival.
Methods: Performing immunohistochemistry and immunoblot analysis, we determined expression of DDX11
in melanoma tissues and cell lines. Following transfection of melanoma cells with a DDX11-specific siRNA,
we conducted a qPCR analysis to determine downregulation of DDX11 in the transfected melanoma cells.
In subsequent studies, which focused upon an analysis of fluorescently labeled as well as Giesma-stained
chromosome spreads, a proliferation analysis and apoptosis assays, we determined the impact of suppressing
DDX11 expression on melanoma cells representing advanced melanoma.
Result: The findings of the study presented herein document that DDX11 is upregulated with progression from
noninvasive to invasive melanoma, and that it is expressed at high levels in advanced melanoma. Furthermore,
and equally important, we demonstrate that blocking the expression of DDX11 leads not only to inhibition of
melanoma cell proliferation and severe defects in chromosome segregation, but also drives melanoma cells rapidly
into massive apoptosis.
Conclusion: To date, little is known as to whether helicases play a role in melanoma development and specifically,
in the progression from early to advanced melanoma. In this report, we show that the helicase DDX11 is expressed
at high levels in primary and metastatic melanoma, and that interfering with its expression leads to severe
chromosome segregation defects, telomere shortening, and massive melanoma cell apoptosis. These findings
suggest that DDX11 could be an important candidate for molecular targeted therapy for advanced melanoma.
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Molecular therapy targeting the BRAFV600E mutation
and anti-CTLA-4 antibody-based immunotherapy have
shown some benefit for patients with advanced melan-
oma. However, in light of the fact that advanced melan-
oma, rapidly and very aggressively, mounts resistance to
BRAF small-molecule inhibitor treatment; anti-CTLA-4
immunotherapy has efficacy in less than 10-20% of
melanoma patients; and advanced melanomas harbor* Correspondence: dbecker@pitt.edu
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distribution, and reproduction in any mediumneither a large number of gene fusions or chimeric tran-
scripts [1] nor with the exception of the BRAFV600E
mutation, a high rate of mutations [2,3], the pertinent
challenge regarding this disease continues to be the
identification of genes that are upregulated to high levels
in advanced melanoma, and when inhibited in their
function, cause primary and metastatic melanoma cells
to undergo apoptosis.
In line with our long-term effort to identify genes that
are upregulated with progression from early to advanced
melanoma, we recently profiled archived, formalin-fixed
paraffin-embedded tissue samples representing early asentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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The data from this whole-genome expression analysis
revealed that one of the identified genes, upregulated to
substantial levels with progression from noninvasive
melanoma in situ > to invasive radial growth phase mel-
anoma > primary melanoma > metastatic melanoma is
the gene DDX11, which has never before been asso-
ciated with melanoma.
First isolated as the human homologue of the yeast
CHL1 gene [4,5], DDX11 (alias ChlR1) is a member of
the DEAD/DEAH box family of helicases, which com-
prises more than 40 members. Sharing sequence similar-
ity with the FANCJ helicase and the DEAH-box
helicases, XPD and RTEL [6], DDX11 is essential for the
cohesion of chromosome arms and centromeres and
when depleted, mitotic failure occurs due to replicated
chromosomes failing to segregate after prometaphase ar-
rest [7]. More recently, biallelic mutations in DDX11
have been identified as the cause of the Warsaw break-
age syndrome cohesinopathy, which among other
clinical manifestations is associated with abnormal skin
pigmentation [8].
The findings of our study, summarized herein, demon-
strate that DDX11 is expressed at high levels in primary
and metastatic melanomas, but not in melanocytes of
normal skin, atypical nevi, or melanoma in situ, and that
suppressing DDX11 expression in advanced melanomas
leads to severe defects in chromosome segregation, and
with potential relevance to therapeutic intervention,
inhibition of melanoma cell proliferation and rapid
melanoma cell death.
Results
Status and pattern of DDX11 expression in normal skin,
nevus and melanoma tissues, and melanoma cell lines
To identify genes that are upregulated with progression
from noninvasive melanoma in situ (MIS) to radial
growth phase (RGP) melanoma, which is the first stage
of invasive melanoma, we recently subjected RNAs iso-
lated from archived, formalin-fixed paraffin-embedded
(FFPE) tissue samples representing these two stages of
early melanoma development to whole-genome DASL
HT BeadChip arrays. Analysis of the not background
subtracted, but quantile normalized data of this whole-
genome expression profiling study, which as a subse-
quent step, included a stringent Ingenuity Pathway (IPA)
core analysis, revealed that DDX11, a gene never before
associated with melanoma, was upregulated 8-fold in
RGP melanoma compared with MIS.
DDX11 (alias ChlR1), one of the members of the
DEAD/DEAH box family of helicases, is required for the
cohesion of chromosome arms and centromeres [5,7,9]
and thus, plays an important role in maintaining genome
stability. In view of the fact that, to date, little is knownregarding the role of helicases in melanoma and likewise,
regarding genes that have pertinent functions in main-
taining chromosome transmission fidelity and genome
stability in melanoma cells, we deemed it important to
characterize the function(s) of DDX11 in melanoma. As
a first step towards this goal, we performed immunohis-
tochemistry analysis of tissues as well as immunoblot
analysis of cell lines to determine the status and pat-
tern of DDX11 expression in normal skin, nevus and
melanoma tissues, and in cell lines representing primary
melanoma in the vertical growth phase (VGP melan-
oma) and melanoma in the metastatic growth phase
(MGP melanoma).
Immunohistochemistry analysis of cryopreserved tis-
sue sections, prepared from normal skin, atypical nevi,
which are the precursors and risk markers of melanoma,
MIS, and advanced melanomas, with an antibody to
human DDX11 revealed strong expression of DDX11 in
advanced melanoma comprised of VGP and MGP mela-
nomas and melanoma-infiltrated lymph nodes (LN)
(Figure 1A). In contrast, DDX11 expression was not
detected in epidermal melanocytes of normal skin (NS)
(Figure 1A) - a finding that is in agreement with the
data of a previous study, which showed that DDX11
is expressed at extremely low levels in normal human
skin [4]. Likwise, neither atypical nevocytes (AN)
(Figure 1A), which are clusters of melanocytes nor MIS
cells showed expression of DDX11 (Figure 1A). Similar
to the strong expression of DDX11 detected in tissues
representing advanced melanoma, subsequent immuno-
blot analysis revealed that DDX11 is also strongly
expressed in cell lines representing VGP (Figure 1B, lane
a) and MGP melanoma (Figure 1B, lanes b-d). We did
not include in the immunoblot analysis, protein lysates
representing atypical nevocytes, MIS, or RGP melanoma
cells, because none of these cells can be propagated
in vitro.
Since it been reported that DDX11 has a dynamic
localization during mitosis [7], we performed in addition
to the immunohistochemistry and immunoblot analyses,
a DDX11-based immunofluorescence analysis of
WM1158 MGP melanoma cells, which as shown in
Figure 1B, lane d, exhibited clearly detectable expression
of the 108 kD DDX11 protein. Not pretreated with any
agent to enrich for cells in mitosis, staining of WM1158
MGP melanoma cells with the DDX11 antibody served
to show expression and localization of DDX11 during
interphase (Figure 1C, lane a) and the subsequent stages
of mitosis (Figure 1C, lanes b-e).
Downregulation of DDX11 expression severely impairs
the morphology of melanoma cells
Alternative splicing of the evolutionary highly conserved
human DDX11 gene, located on chromosome 12p11,
Figure 1 DDX11 expression in normal skin, nevi, and melanoma tissues and cell lines. (A) Cryopreserved tissue sections, representing
normal human skin (NS), atypical nevus (AN), melanoma in situ (MIS), VGP melanoma (VGP), MGP melanoma (MGP), and melanoma-infiltrated
lymph node (LN), were stained with an antibody to human DDX11 and counterstained with hematoxylin. Images were captured at 10X
magnification. (B) Immunoblot analysis of VGP melanoma cells WM983-A (a), and MGP melanoma cells WM983-B (b), WM852 (c), and WM1158
(d) probed with DDX11 antibody. For loading control, the immunoblot was probed with an antibody to α-tubulin. (C) Immunofluorescence
analysis of DDX11 expression in MGP melanoma cells, WM1158, during interphase (a), prophase (b), metaphase (c), telophase (d) and late
telophase (e). The melanoma cells were probed with an antibody to human DDX11 (pseudocolored red), and their nuclei (pseudocolored blue)
counterstained with fluorescent DAPI.
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advanced melanomas, yields several transcript variants
of slightly different length. Depicted in Figure 2A, panel
a, are schematic presentations of transcript variant 1 and
protein isoform 1 of human DDX11. To determine
whether inhibiting expression of DDX11 in human mel-
anoma cells would interfere with the cells’ proliferation
and possibly some of their other biologic characteristics,
we used a DDX11-specific siRNA that targeting a 25 bp
region in exon 3 of human DDX11 (Figure 2A, panel a),
was previously reported to downregulate human DDX11
[10]. To ascertain effective uptake of this specific siRNA,
we transfected WM1158 MGP melanoma cells with
5 nM of the DDX11 siRNA that we had conjugated tothe cyanine dye, Cy5. As shown in Figure 2A, panel b,
imaging analysis, performed 24 hr after transfection, did
reveal the presence of the DDX11 siRNA in these mel-
anoma cells.
To assess whether following transfection of melanoma
cells with the DDX11 siRNA, DDX11 mRNA would be
downregulated, we transfected WM1158 MGP melan-
oma cells with 25 nM of the DDX11 siRNA not conju-
gated to Cy5, and serving as control, with 25 nM of a
pool of siRNAs comprised of four non-targeting siRNAs.
Using a pair of qPCR primers spanning exons 20–22
of human DDX11 (Figure 2A, panel a), we performed
qPCR analysis, which as depicted for the 48 hr time
point post transfection (Figure 2B), revealed that
Figure 2 Analysis of DDX11 siRNA-transfected melanoma cells. (A, panel a) Schematic presentation of human DDX11 transcript variant 1,
and protein isoform 1. The red-colored symbol above exon 3 in transcript 1 marks the position of the DDX11 siRNA, and the green-colored bar
symbol above exons 20–22, indicates the location of the DDX11 qPCR primers used in the qPCR analysis. (A, panel b) Immunofluorescence
analysis of WM1158 MGP melanoma cells at 24 hr following transfection with 5 nM of Cy5-conjugated DDX11 siRNA (pseudocolored yellow).
Nuclei (pseudocolored blue) were counterstained with fluorescent DAPI. (B) qPCR analysis of WM1158 MGP melanoma cells that had received
only Lipofectamine 2000 (black-colored bar), or were transfected with 25 nM of control siRNAs (grey-colored bar) or DDX11 siRNA (red-colored
bar) for 48 hr. (C) Phase-contrast images, captured at 10X magnification, depicting the morphology WM1158 MGP melanoma cells following
transfection with 150 nM of control siRNAs for 96 hr (a) or with 1 nM (b), 25 nM (c) or 150 nM (d) of DDX11 siRNA for 24 hr. The red-colored
arrow in the phase-contrast images, shown in panels c and d, points to the chain-like morphology of melanoma cells that did not separate.
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with WM1158 MGP melanoma cells that had received
only the siRNA delivery vehicle Lipofectamine 2000, or
the pool of the control siRNAs.
The most prominent phenotypic change we observed
during this series of experiments was that compared
with control siRNA transfected cells (Figure 2C, panel
a), melanoma cells that had been transfected with
the DDX11 siRNA, exhibited a rapid and dramatic alter-
ation in their morphology. Specifically, we found that as
shown in Figure 2C, panels b-d, transfection of theDDX11 siRNA caused melanoma cells to lose cell-cell
contact in as little as 24 hr, and at doses of 25 nM
as well as 150 nM of DDX11 siRNA, a significant
number of the transfected melanoma cells exhibited a
tightly held together chain-like morphology (Figure 2C,
panels c and d).
Inhibition of DDX11 expression leads to chromosome
segregation defects in melanoma cells
To gain insights into the cause(s) of the DDX11 siRNA-
induced morphologic changes, we transfected melanoma
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chromosome spreads that were stained with either fluor-
escent DAPI or Giemsa solution. Compared with the
DAPI-stained chromosome spreads of melanoma cells
that had been transfected for 24 hr with the control
siRNA pool (Figure 3A, panel a), the DAPI-stained
chromosome spreads of DDX11 siRNA-transfected
melanoma cells (Figure 3A, panel b) revealed a pattern
of tightly condensed chromosomes. This difference in
chromosome abnormality became even more apparent
when the chromosome spreads of control siRNA
(Figure 3B, panel a) and DDX11 siRNA-transfected mel-
anoma cells (Figure 3B, panels b and c) were stained
with Giemsa.
Since it has been reported that DDX11 plays an im-
portant role in maintaining fidelity of chromosome arm
cohesion prior to mitosis [11], we next determined in a
total of 40 chromosome spreads prepared from the
DDX11 siRNA-transfected and likewise, the control
siRNA-transfected melanoma cells, the number of
chromosomes that had closed, partially closed, or open/
separated arms. As displayed in Figure 3C, panel a,Figure 3 Inhibition of DDX11 expression in melanoma cells leads to c
of fluorescent DAPI-stained chromosome spreads (40X magnification) of W
control siRNA (a) or 75 nM of DDX11 siRNA (b). (B) Images of Giemsa-stain
for 24 hr with 75 nM of control siRNAs (a) or 75 nM of DDX11 siRNA (b and
melanoma cells transfected for 24 hr with 75 nM of control siRNAs (grey-co
analyzed for chromosomes with closed, partially closed, or open/separatedcompared with the control, the DDX11 siRNA-
transfected melanoma cells exhibited approximately 50%
fewer chromosomes with closed arms, and about 50-60%
more chromosomes with partially closed or open/
separated arms. Furthermore, and even more apparent
was that the average length of the chromosomes of
the DDX11 siRNA-transfected melanoma cells was
significantly shorter than the length of the chromo-
somes of the control siRNA-transfected melanoma cells
(Figure 3C, panel b).
Suppression of DDX11 expression severely impairs
melanoma cell proliferation and causes massive
melanoma cell apoptosis
To determine whether in addition to the observed
defects in chromosome segregation, inhibition of
DDX11 expression would result in interference with
other biological features of melanoma cells, we trans-
fected melanoma cells (1x105/60 mm plate) with 25 nM
of DDX11 or 25 nM of the pool of control siRNAs.
Twenty-four hours after transfection, and every 24 hr
thereafter, we determined the rate of cell proliferation.hromosome segregation defects. (A) Immunofluorescence analysis
M1158 MGP melanoma cells transfected for 24 hr with 75 nM of
ed chromosome spreads of WM1158 MGP melanoma cells transfected
c). (C) Giemsa-stained chromosome spreads of WM1158 MGP
lored bars) or 75 nM of DDX11 siRNA (red-colored bars) were
arms (panel a) as well as average length of chromosomes (panel b).
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vided strong evidence that unlike melanoma cells that
had received only Lipofectamine 2000 or were trans-
fected with the control siRNAs, downregulation of
DDX11 expression strongly inhibited the cells’ prolifera-
tion even as long as 96 hr post transfection. In light of
the fact that DDX11 is an evolutionary highly conserved
gene, it is of interest to note that in the absence of chl-1
(DDX11), C. elegans animals have been found to have
proliferation defects in their soma and germline [12],
and that in mammalian cells, DDX11 interacts with the
proliferating cell nuclear antigen (PCNA) [9].
However, the most severe DDX11 siRNA-induced
alteration we detected was manifest in the fact that
the cells rapidly and massively underwent apoptosis.
Depicted in Figure 4B, lanes d-g are the results of a c-
PARP immunoblot analysis, which as reflected by
cleavage of PARP to cPARP, documented that WM1158
MGP melanoma cells underwent apoptosis as early as
48 hr following transfection of the DDX11 siRNA
(Figure 4B, lane e). In comparison, immunoblot analysisFigure 4 Suppressing DDX11 expression in melanoma cells leads to i
cell apoptosis. (A) Proliferation of WM1158 MGP melanoma cells that rece
with 25 nM of control siRNAs (grey-colored line) or 25 nM of DDX11 siRNA
transfection is the mean of duplicate samples analyzed. (B) Immunoblot an
DDX11 siRNA for 24 hr (d), 48 hr (e), 72 hr (f) or 96 hr (g), were probed wit
WM1158 cells that were not transfected (a), had received only Lipofectamin
served as controls. For loading control, the immunoblot was probed with a
for 48 hr with 75 nM of control siRNAs (a) or 75 nM of DDX11 siRNA (b) we
that had undergone apoptosis are pseudocolored red (TUNEL staining) andof WM1158 MGP melanoma cells that were not trans-
fected (Figure 4B, lane a), had received only Lipofecta-
mine 2000 (Figure 4B, lane b), or were transfected with
25 nM of the pool of control siRNAs (Figure 4B, lane c),
did not demonstrate cleavage of PARP to cPARP even at
96 hr post transfection (Figure 4B, lanes a-c). A similar
result was obtained by performing a TUNEL assay. Mel-
anoma cells that as demonstrated in Figure 4C, panel a,
had been transfected for 48 hr with 75 nM of the pool
of four control siRNAs, did not reveal any TUNEL stain-
ing, but melanoma cells that had received the DDX11
siRNA clearly exhibited apoptosis as reflected by strong
TUNEL staining (Figure 4C, panel b).
Discussion
The findings of the study presented herein provide evi-
dence that the DEAD/H (Asp-Glu-Ala-Asp/His) box
helicase, DDX11, is upregulated with progression from
early to advanced melanoma, and that this gene plays a
pivotal role in shielding advanced melanomas from
chromosome segregation defects and apoptosis.nhibition of melanoma cell proliferation and massive melanoma
ived only Lipofectamine 2000 (black-colored line) or were transfected
(red-colored line). Depicted at each time point following siRNA
alysis of WM1158 MGP melanoma cells, transfected with 25 nM of
h an antibody to c-PARP. Protein lysates prepared at 96 hr from
e 2000 (b), or were transfected with 25 nM of control siRNAs (c)
n antibody to α-tubulin. (C) WM1158 MGP melanoma cells, transfected
re analyzed by immunofluorescence-based TUNEL. Melanoma cells
fluorescent DAPI-counterstained nuclei are pseudocolored blue.
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cious immunotherapies for advanced melanoma, and
more recently by the focus on molecular therapy to tar-
get BRAF-mutated melanomas, considerably less atten-
tion has been paid to genes that are not only
upregulated to high levels in advanced melanoma, but
also play a pertinent role in protecting VGP and MGP
melanomas from apoptosis. In a recent study [13], we
documented by way of molecular targeting of the cell
cycle regulator, CDK2, that VGP and MGP melanoma
cells are highly vulnerable to interference with their pro-
gression through S phase. The data, summarized herein,
provide not only further and strong support for this ob-
servation, but also demonstrate that inhibiting expres-
sion of a helicase such as DDX11, which has a vital
function in sister chromatid cohesion [7,9,11], is dele-
terious for melanoma cells.
Thus far, little is known regarding the involvement,
function, and importance of helicases in the progression
from early to advanced melanoma, and their role in
locally advanced and/or stage IV melanoma. Melanoma
differentiation antigen 5 (MDA5), which comprises a
caspase activation and recruitment domain (CARD) and
an RNA helicase domain with ATP-dependent RNA-
unwinding activity, was first isolated from a melanoma
cell line [14]. However, induced by Interferon-β (IFN-β),
MDA5 is not expressed in cells representing advanced
melanoma unless the cells are treated with the cytokine.
A second helicase, recently shown to be expressed in a
subpopulation of melanoma cells, referred to as ABCB5+
malignant melanoma-initiating cells, is HAGE (alias Can-
cer/testis antigen 13 (CT13); DDX43) [15]. HAGE was
shown to promote proliferation and tumor growth of this
subpopulation of melanoma cells, and to regulate AKT
and ERK phosphorylation through NRAS [15].
The novel and important findings regarding the herein
described pivotal role of DDX11 in advanced melanoma
is that following inhibition of DDX11 expression, the
cells not only exhibited a significantly higher number
of chromosomes with partially closed as well as open/
separated arms, but also that compared with the control,
the average length of their chromosomes was shorter.
To date, little if anything is known about how VGP and
MGP melanoma cells guard against DNA damage, con-
trol and maintain their genome stability, and related to
these survival processes, retain telomere length. In the
context of a study published a few years ago [16], a hy-
pothesis was put forward but not tested that DDX11
might be involved in telomere length determination.
Recently, however, it has been documented that loss
of DDX11 leads to changes in telomeric chromatin for-
mation [17], and that DDX11 interacts with the flap
structure-specific endonuclease 1 (FEN-1) gene [9],
which has a vital role in telomere stability. Thus, it ispossible that like DDX39, which when overexpressed
leads to progressive telomere elongation and to telomere
shortening when depleted [18], DDX11 has an important
function in maintaining telomere length and stability in
a malignancy such as advanced melanoma. The second
and even more pertinent finding described herein is
that inhibition of DDX11 expression leads to rapid
and massive melanoma cell apoptosis. In the context of
mouse mutant studies, it has been shown that loss of
Ddx11 causes apoptosis [11,19], but this is the first study
which shows that inhibiting DDX11 expression in a
malignancy that is refractory to virtually all apoptosis-
inducing agents/therapies, leads to rapid and massive
programmed cell death.
The biochemical functions of DDX11 have been
established [20], but hitherto, a DDX11-specific small-
molecule inhibitor is not available that would make it
possible to systemically treat human melanoma xeno-
grafts and establish in vivo, therapeutic efficacy of block-
ing the function of DDX11. Given the possibility that like
in the case of the Werner syndrome helicase [21], a
human DDX11-specific small-molecule inhibitor will be
isolated in the near future, it will be of importance to
determine whether systemic therapy with such an inhibi-
tor, alone or in combination with an inhibitor that blocks
the function of FGFR1, which together with bFGF
(FGF2) is a key regulator of melanoma proliferation, will
have efficacy for advanced melanomas, and in particular
for melanomas that are BRAF wild-type, which are the
most aggressive type of advanced melanoma. Another
interesting and important aspect that begs exploration is
whether there is a link between DDX11 and pigmenta-
tion. Genetic disorders such as Bloom syndrome, Fan-
coni anemia, and the recently identified cohesinopathy,
Warsaw breakage syndrome [8], are associated with
abnormal skin pigmentation. Thus, it is a possibility that
there is link between helicases such as DDX11 and the
microphthalmia-associated transcription factor (MITF),
which is a master regulator of melanocyte development.
In addition to the findings of our study presented
herein, novel and compelling evidence that some mem-
bers of the family of DEAD box helicases have pertinent
functions in certain types of cancer has recently also
been obtained in two other cases – one being breast
cancer and the other medulloblastoma, which like mel-
anoma is a neural crest-derived malignancy. In the case
of breast cancer, the DEAD box helicase, DDX5, was
found to be amplified and often co-amplified along with
ERBB2, and breast cancer cell lines with amplification of
the DDX5 locus were considerably more sensitive to its
knockdown than breast cancer cell lines lacking this
amplification [22]. In the case of WNT-subgroup medul-
loblastomas that unlike the other three medulloblastoma
subtypes have a good long-term prognosis, exome
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gene DDX3X [23-25], which is a paralogue of the DEAD
box helicase, DDX3.
Conclusions
The novel finding presented herein documents that
DDX11, a member of the DEAD-box family of helicases,
is expressed at high levels in primary and metastatic
melanoma, but not in melanocytes of normal skin. Fur-
thermore, our data demonstrate that interfering with the
expression of DDX11 has severe consequences for mel-
anoma cells. In particular, we document that inhibiting
DDX11 expression causes substantial chromosome seg-
regation defects and telomere shortening, major inhib-
ition of melanoma cell proliferation, and rapid and
massive melanoma cell apoptosis. Taken together, these
data suggest that molecular targeting of DDX11 could
be a new avenue and powerful approach to treat
advanced melanoma, which is refractory to chemother-
apy and radiation therapy.
Methods
Melanoma cell lines and tissues
VGP (WM983-A) and MGP (WM983-B, WM852,
WM1158) human melanoma cell lines were propagated
in vitro as previously described [26]. Standard immuno-
histochemistry analysis of deidentified, post-diagnosis
excess cryopreserved 20 human tissue samples (deemed
exempted (4e) by the University of Pittsburgh IRB),
representing normal skin, atypical nevus, melanoma in
situ, VGP melanoma, MGP melanoma, and melanoma-
infiltrated lymph nodes was performed with an anti-human
DDX11 mouse monoclonal antibody (Sigma-Aldrich,
St. Louis, MO, USA). The chromogen used in the immu-
nohistochemistry analysis was Vulcan Fast Red, and all
DDX11 antibody-probed tissue sections were counter-
stained with hematoxylin.
Immunoblot and immunofluorescence analysis
Protein lysates (25 μg/sample), separated on sodium
dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and
transferred onto nylon membrane, were probed with
antibody to human DDX11 (Sigma-Aldrich) or α-tubulin
(Cell Signaling Technology, Inc., Danvers, MA, USA),
followed by incubation with a horseradish peroxidase-
conjugated secondary antibody (Cell Signaling Technol-
ogy) and Luminol reagent (Millipore, Billerica, MA, USA).
For immunofluorescence analysis, melanoma cells
were fixed with 2% paraformaldehyde (2 min at room
temperature) and thereafter, with methanol (30 min at
−20°C). The fixed cells were subsequently blocked with
goat serum, probed with primary antibody to human
DDX11 (Sigma-Aldrich) followed by an Alexa Fluor 555-
conjugated secondary antibody (Invitrogen, Carlsbad,CA, USA), counterstained with fluorescent 40-6-diami-
dino-2-phenylindole (DAPI) (Invitrogen), and imaged
with an inverted, epifluorescent TE2000 Nikon micro-
scope and a charge-coupled device (CCD) camera (Roper
Scientific, Inc./Photometrics, Tucson, AZ, USA).
DDX11 siRNA conjugation and transfection
Five μg of a custom-synthesized siRNA (Thermo Fisher
Scientific Dharmacon (Lafayette, CO, USA) based upon
the human DDX11 exon 3-specific sequence 5’ CCU
GUG UCU GUC UUC UUC CUG CGA A 3’ [10], which
as we determined via a BLAST search, does not align
with any other sequence, was conjugated to the fluoro-
chrome Cy5 via a Label IT siRNA Tracker Intracellular
Localization Cy5 kit (Mirus Bio LLC, Madison, Wl,
USA). Melanoma cells, transfected for 24 hr with 5 nM
of the Cy5-conjugated DDX11 siRNA, were fixed with
4% paraformaldehyde, counterstained with fluorescent
DAPI (Invitrogen), and imaged. Dual color images were
processed with MetaMorph software 7.7.5.0 (Molecular
Devices, LLC, Sunnyvale, CA, USA).
Melanoma cells were transfected with the single
DDX11 siRNA not conjugated or a control ON-
TARGETplus non-targeting siRNA pool using Lipofecta-
mine 2000 (Invitrogen) as the siRNA delivery vehicle.
Phase-contrast images of the transfected melanoma cells
were acquired with an inverted, epifluorescent TE2000
Nikon microscope and a CCD camera (Roper Scientific,
Inc./Photometrics).
qPCR analysis
Total RNA was isolated from DDX11 and control siRNA
transfected melanoma cells with Trizol reagent (Sigma-
Aldrich) and in each case, cDNA was transcribed with
qscript cDNA Supermix (Quanta BioSciences, Inc.,
Gaithersburg, MD, USA) from 1 μg of RNA. qPCR reac-
tions were performed with a pair of qPCR primers (life
technologies/Applied Biosystems, Foster City, CA, USA)
spanning human DDX11 exon boundary 20–22 that
generated an 88 bp amplicon. A set of human 18s RNA
primers (life technologies/Applied Biosystems) served
as the internal control. Using PerfeCTa FastMix II, ROX
(Quanta BioSciences, Inc.), 40 qPCR cycles (3 min at 95°C,
15 seconds at 95°C, 1 min at 95°C) were carried out via
a StepOnePlus Real-Time PCR system (life technologies/
Applied Biosystems). The qPCR data were analyzed using
the 2-ΔΔCT method.
Chromosome staining and analysis
Following siRNA transfection, melanoma cells were trea-
ted for 90 min with 100 ng/ml of colchicine, followed by
addition of hypotonic buffer (0.075 M KCl) for 15 min
at 37°C and subsequent fixation with Carnoy's solution.
The chromosome spreads were stained with fluorescent
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stained chromosome spreads were captured with an
inverted, epifluorescent TE2000 Nikon microscope and
a CCD camera (Roper Scientific, Inc./Photometrics).
Images of the Giemsa-stained chromosome spreads were
acquired with a Hamamatsu NanoZoomer 2.0-HT
(Hamamatsu Corporation USA, Bridgewater, NJ, USA).
The number of chromosomes with closed, partially
closed, or open/separated arms was determined for 40
Giemsa-stained chromosome spreads. The ‘Linear Meas-
ure’ tool in the NDP.view software (Hamamatsu Corpor-
ation) was used to determine the length of three
randomly selected chromosomes in each of 50 Giemsa-
stained chromosome spreads.
Proliferation and apoptosis analysis
Melanoma cell proliferation was determined by counting
cells with a hemocytometer. At each time point, dupli-
cate samples were analyzed for DDX11 as well as control
siRNA-transfected cells, and cells that had received only
Lipofectamine 2000 (Invitrogen).
Whole-cell lysates (30 μg/sample) of melanoma cells
transfected with DDX11 or control siRNA were sepa-
rated by SDS-PAGE, transferred onto nylon membrane,
and probed with antibody to c-PARP (Cell Signaling
Technology, Inc.) or α-tubulin (Cell Signaling Technol-
ogy, Inc.), followed by incubation with a horseradish
peroxidase-conjugated secondary antibody (Cell Signal-
ing Technology) and Luminol reagent (Millipore).
For immunofluorescence-based detection of apoptosis,
cytospin preparations of DDX11 as well as control
siRNA-transfected melanoma cells were fixed, permea-
blized, labeled with the In Situ Cell Death Detection Kit,
TMR red (Roche Applied Science, Indianapolis, IN, USA),
counterstained with fluorescent DAPI, and imaged.
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